Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 12627 | 830 | 43.1 | 72% |
Classes in level above (level 2) |
| ID, lev. above |
Publications | Label for level above |
|---|---|---|
| 194 | 20736 | CARBOHYDRATE RESEARCH//JOURNAL OF CARBOHYDRATE CHEMISTRY//GLYCOSIDASE INHIBITORS |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | TUMOR VACCINOL | Address | 23 | 69% | 2% | 20 |
| 2 | GLYCOPEPTIDES | Author keyword | 12 | 12% | 11% | 90 |
| 3 | CARL S MARVEL S | Address | 10 | 73% | 1% | 8 |
| 4 | ANTITUMOR VACCINES | Author keyword | 8 | 62% | 1% | 8 |
| 5 | TUMOR ANTIGEN IMMUNOCHEM | Address | 6 | 80% | 0% | 4 |
| 6 | O LINKED GLYCOPEPTIDE | Author keyword | 6 | 100% | 0% | 4 |
| 7 | SOLID PHASE GLYCOPEPTIDE SYNTHESIS | Author keyword | 5 | 55% | 1% | 6 |
| 8 | O LINKED GLYCOPEPTIDES | Author keyword | 4 | 75% | 0% | 3 |
| 9 | SIALYL T ANTIGEN | Author keyword | 4 | 75% | 0% | 3 |
| 10 | CLIN IMMUNOL SERV | Address | 4 | 20% | 2% | 17 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | GLYCOPEPTIDES | 12 | 12% | 11% | 90 | Search GLYCOPEPTIDES | Search GLYCOPEPTIDES |
| 2 | ANTITUMOR VACCINES | 8 | 62% | 1% | 8 | Search ANTITUMOR+VACCINES | Search ANTITUMOR+VACCINES |
| 3 | O LINKED GLYCOPEPTIDE | 6 | 100% | 0% | 4 | Search O+LINKED+GLYCOPEPTIDE | Search O+LINKED+GLYCOPEPTIDE |
| 4 | SOLID PHASE GLYCOPEPTIDE SYNTHESIS | 5 | 55% | 1% | 6 | Search SOLID+PHASE+GLYCOPEPTIDE+SYNTHESIS | Search SOLID+PHASE+GLYCOPEPTIDE+SYNTHESIS |
| 5 | O LINKED GLYCOPEPTIDES | 4 | 75% | 0% | 3 | Search O+LINKED+GLYCOPEPTIDES | Search O+LINKED+GLYCOPEPTIDES |
| 6 | SIALYL T ANTIGEN | 4 | 75% | 0% | 3 | Search SIALYL+T+ANTIGEN | Search SIALYL+T+ANTIGEN |
| 7 | O GLYCOPEPTIDES | 3 | 50% | 1% | 5 | Search O+GLYCOPEPTIDES | Search O+GLYCOPEPTIDES |
| 8 | GLOBO H | 3 | 43% | 1% | 6 | Search GLOBO+H | Search GLOBO+H |
| 9 | CARBOHYDRATE BASED ANTITUMOR VACCINES | 3 | 100% | 0% | 3 | Search CARBOHYDRATE+BASED+ANTITUMOR+VACCINES | Search CARBOHYDRATE+BASED+ANTITUMOR+VACCINES |
| 10 | GLYCOPEPTIDE ANTIGENS | 3 | 100% | 0% | 3 | Search GLYCOPEPTIDE+ANTIGENS | Search GLYCOPEPTIDE+ANTIGENS |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | O GLYCOPEPTIDES | 29 | 52% | 5% | 40 |
| 2 | GLOBO H ANTIGEN | 24 | 91% | 1% | 10 |
| 3 | ANTITUMOR VACCINES | 23 | 59% | 3% | 26 |
| 4 | ANTICANCER VACCINE | 21 | 69% | 2% | 18 |
| 5 | SIALOSYL TN EPITOPE | 21 | 78% | 2% | 14 |
| 6 | TANDEM REPEAT GLYCOPEPTIDE | 21 | 78% | 2% | 14 |
| 7 | ANTICANCER VACCINES | 19 | 44% | 4% | 33 |
| 8 | EPITHELIAL MUCIN MUC4 | 18 | 89% | 1% | 8 |
| 9 | IMMUNOLOGICAL ADJUVANT QS 21 | 16 | 43% | 3% | 28 |
| 10 | PENTAFLUOROPHENYL ESTERS | 15 | 39% | 4% | 30 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| Development of Globo-H Cancer Vaccine | 2015 | 1 | 23 | 65% |
| Recent development in carbohydrate-based cancer vaccines | 2009 | 54 | 49 | 76% |
| The development of synthetic antitumour vaccines from mucin glycopeptide antigens | 2013 | 34 | 70 | 57% |
| Glycodendrimers as functional antigens and antitumor vaccines | 2012 | 33 | 78 | 51% |
| From the laboratory to the clinic: A retrospective on fully synthetic carbohydrate-based anticancer vaccines | 2000 | 323 | 132 | 31% |
| Immunotherapy for cancer: synthetic carbohydrate-based vaccines | 2009 | 67 | 165 | 33% |
| Synthetic carbohydrate-based anticancer vaccines: the Memorial Sloan-Kettering experience | 2009 | 31 | 78 | 56% |
| Synthesis of glycopeptides containing carbohydrate and peptide recognition motifs | 2000 | 217 | 214 | 37% |
| Synthetic carbohydrate-based antitumor vaccines: challenges and opportunities | 2005 | 39 | 38 | 74% |
| Glycopeptides as versatile tools for glycobiology | 2006 | 89 | 179 | 28% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | TUMOR VACCINOL | 23 | 69% | 2.4% | 20 |
| 2 | CARL S MARVEL S | 10 | 73% | 1.0% | 8 |
| 3 | TUMOR ANTIGEN IMMUNOCHEM | 6 | 80% | 0.5% | 4 |
| 4 | CLIN IMMUNOL SERV | 4 | 20% | 2.0% | 17 |
| 5 | SOLID TUMOR IMMUNOL | 3 | 100% | 0.4% | 3 |
| 6 | PREPARAT SYNTH CORE IL | 3 | 42% | 0.6% | 5 |
| 7 | DEV TUMOR VACCINOL | 2 | 67% | 0.2% | 2 |
| 8 | ISAS LEIBNIZ ANALYT SCI | 2 | 67% | 0.2% | 2 |
| 9 | ORGAN SYNTH CORE | 2 | 40% | 0.5% | 4 |
| 10 | GENITOURINARY SOLID TUMOR ONCOL | 1 | 100% | 0.2% | 2 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000226564 | TN ANTIGEN//SIALYL TN//SIALYL TN ANTIGEN |
| 2 | 0.0000193167 | AMINOPOLYSTYRENE//BETA GLYCOPYRANOSYLAMINES//BETA N ACETYLGLUCOSAMINYL L ASPARAGINE ANALOGUES |
| 3 | 0.0000163251 | GLYCOSYLATIONS//OLIGOSACCHARIDE SYNTHESIS//THIOGLYCOSIDES |
| 4 | 0.0000138348 | CLIN SHINJUKU KU//NEPHRITOGENOSIDE//GLYCOPYRANOSYLAMINE |
| 5 | 0.0000121657 | NATIVE CHEMICAL LIGATION//PEPTIDE THIOESTER//PEPTIDE THIOESTERS |
| 6 | 0.0000110478 | MUC1//MUC1 MUCIN//MUC 1 |
| 7 | 0.0000108055 | C MANNOSYLATION//PEPTIDE PROT CHEM BIOL//SOSCO EA 4505 |
| 8 | 0.0000089724 | 2 CHLOROTRITYL RESIN//PROTECTED PEPTIDES//SOLID PHASE PEPTIDE SYNTHESIS |
| 9 | 0.0000089204 | N ACETYLNEURAMINATE LYASE//N ACETYLNEURAMINIC ACID//KDN |
| 10 | 0.0000088729 | REVERSE HYDROLYSIS//TRANSGLYCOSYLATION//ALMOND BETA GLUCOSIDASE |